Alex Morozov

… market has been treating big pharma too harshly and that these stocks are poised to bounce back. As Morningstar's Alex Morozov recently noted , the big drugmakers have become much more efficient while also lowering expectations, setting the stage …

… Covidien, whose shares have risen more than 30% since the end of the second quarter of 2010. Morningstar analyst Alex Morozov thinks that the stock still has some room to run, especially as the medical device maker continues to use its strong …

… a discount to their intrinsic value. Below, five analysts provide a short pitch on a top personal stock holding: Alex Morozov – Director, Healthcare Top Personal Holding: Autodesk ADSK Morningstar Rating: Moat Rating: Wide “Autodesk …

… resilient tag no longer seems applicable for health care," writes Morningstar associate director of equity research Alex Morozov , as an unprecedented slowdown in demand for health-care goods and services has dragged on these stocks. What's …

… manufacturing health care products ranging from needles to sophisticated diagnostic equipment. Morningstar analyst Alex Morozov cites the firm's defensible competitive position, manufacturing scale, technological prowess, and competent management …

… investing in research and development, bolstering its salesforce, and pruning its product lineup, Morningstar analyst Alex Morozov believes that Covidien has returned to prominence in the medical device arena. He thinks that Covidien's strategy …

… technological prowess , and competent management team make this health - care bellwether one of Morningstar analyst Alex Morozov 's favorite names in the medical products industry . While not necessarily a high - growth opportunity , Becton offers …

… Star names we came across in the holdings of these six managers but also a long - standing top buy idea of our analyst Alex Morozov . Looking for Value in Different Places The path to outperformance taken by Columbia Value & Restructuring involved …